Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PLD2 | O14939 | 8/20 | 0.37 |
| ▸ | PLD1 | Q13393 | 8/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14008495 | 0.94 | USP2 (0.43) | PGRUSP2ALDH1A1LMNACHRM2 | |
| Trifluoroacetic Acid SCHEMBL4434600 | 0.83 | USP2 (0.56) | USP2ALDH1A1LMNAKCNH2PLD2 | |
| SCHEMBL14146426 | 0.83 | PGR (0.44) | PGRUSP2ALDH1A1LMNACHRM2 | |
| SCHEMBL4440194 | 0.82 | CHRM2 (0.41) | PGRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14146422 | 0.81 | CHRM2 (0.42) | PGRUSP2ALDH1A1LMNACHRM2 | |
| SCHEMBL4434580 | 0.80 | PLD2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4433004 | 0.80 | SCN9A (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Acetic Acid SCHEMBL4648319 | 0.79 | CHRM2 (0.48) | PGRUSP2ALDH1A1LMNACHRM2 | |
| SCHEMBL5006613 | 0.79 | CHRM2 (0.39) | PGRUSP2ALDH1A1LMNACHRM2 | |
| SCHEMBL14008565 | 0.78 | PLD2 (0.43) | PLD2PLD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | PGR 3199/4885USP2 896/4885ALDH1A1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.